UK trade group lobbies for £140 million investment in biotech industry

23 August 2017
2019_biotech_test_vial_discovery_big

The Medicines Manufacturing Industry Partnership (MMIP) has issued a report seeking government support for the building of four new ‘centers of excellence’ for medicines manufacturing across the UK.

Established in 2014, the MMIP is a joint venture between the British government and the UK biopharmaceutical industry, which conducts research into the UK's position in medicines manufacturing with the aim of boosting the industry.

Asking for an investment of £140 million ($180 million) over three years, the report identifies four funding priorities:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology